Harshini Sriram

Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy

Prashant Tembhare, Harshini Sriram, Twinkle Khanka et al. · Journal for ImmunoTherapy of Cancer · 2020 · 41 citations · Full text

Improved protocol for plasma microRNA extraction and comparison of commercial kits

Harshini Sriram, Nilesh Deshpande, Prashant Tembhare et al. · Biochemia Medica · 2021 · 27 citations · Full text

Eleven‐marker 10‐color flow cytometric assessment of measurable residual disease for T‐cell acute lymphoblastic leukemia using an approach of exclusion

Prashant Tembhare, Gaurav Chatterjee, Twinkle Khanka et al. · Cytometry Part B Clinical Cytometry · 2020 · 25 citations · Full text

Decreased expression of cell adhesion genes in cancer stem-like cells isolated from primary oral squamous cell carcinomas

Amrendra Mishra, Harshini Sriram, Pinal Chandarana et al. · Tumor Biology · 2018 · 14 citations · Full text

Immunophenotypic shift in the B‐cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B‐lymphoblastic leukemia

Gaurav Chatterjee, Harshini Sriram, Sitaram Ghogale et al. · Cytometry Part B Clinical Cytometry · 2020 · 13 citations · Full text